AMT 110

Drug Profile

AMT 110

Alternative Names: AMT-110

Latest Information Update: 20 Sep 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Amsterdam Molecular Therapeutics
  • Developer Institut Pasteur; uniQure
  • Class Gene therapies
  • Mechanism of Action Alpha N acetyl D glucosaminidase replacements; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Mucopolysaccharidosis III

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Mucopolysaccharidosis-III in Netherlands (Intracerebral)
  • 31 May 2016 UniQure initiates a phase I/II extension trial for Mucopolysaccharidosis III in France
  • 04 Apr 2016 UniQure plans a phase I/II extension trial for Mucopolysaccharidosis III in France
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top